A Phase 1 interventional study of REGN4659 and Cemiplimab in Carcinoma, Non-Small-Cell Lung, sponsored by Regeneron Pharmaceuticals. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-13.
Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 27th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 1, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
Georgetown University · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18+
UNICANCER · Sites in France
Ages 18+
ETOP IBCSG Partners Foundation · Sites in Austria, Estonia, France and 6 more countries
Ages 18+
Maia Biotechnology · Sites in Poland, Romania, Taiwan and 1 more country
Ages 18+
By country, each count listing its studies:
cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 22 · Phase 3 6
First in 2017; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 61 across the 29 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 29 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals: 2 open now, 11 under way, 2 of them phase 3. Of 9 finished, 6 (67%) have results posted.
Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2018, is one of 3 in phase 1, and was the 7th registered.
Regeneron Pharmaceuticals’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2008.
3 of the studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06908304Phase 3Maia BiotechnologyA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | 2027-07-31 |
| NCT06088771Icahn School of Medicine at Mount SinaiNeoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC | 2026-12-01 |
| NCT04253964Wake Forest University Health SciencesPilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Regeneron Pharmaceuticals’s 21 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.
KEY Inclusion Criteria:
KEY Exclusion Criteria:
Note: Other protocol defined inclusion/ exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In a single dose escalation cohort, participants will receive cemiplimab alone.
Drug: Cemiplimab
Dose Escalation cohorts: In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination. In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination. Dose Expansion cohorts: In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab.
Drug: REGN4659 · Drug: Cemiplimab
REGN4659 will be administered by intravenous (IV) infusion.
Cemiplimab will be administered by intravenous (IV) infusion.
Also known as: REGN2810
Rate of dose limiting toxicities (DLTs) during the dose escalation phase
Time frame: Up to week 126
Rate of treatment emergent adverse events (TEAEs)
Time frame: Up to week 126
Rate of immune-related adverse events (irAEs)
Time frame: Up to week 126
Rate of serious adverse events (SAEs)
Time frame: Up to week 126
Rate of deaths
Time frame: Up to week 126
Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])
Time frame: Up to week 126
Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during the dose expansion phase
Time frame: Up to week 126
REGN4659 and cemiplimab concentrations in serum over time
Time frame: Up to week 126
ORR based on RECIST 1.1 during the dose escalation phase
Time frame: Up to week 126
ORR based on immune-based therapy Response Evaluation Criteria (iRECIST)
Time frame: Up to week 126
Best overall response (BOR)
Time frame: Up to week 126
Duration of response (DOR)
Time frame: Up to week 126
Disease control rate
Time frame: Up to week 126
Progression-free-survival (PFS) based on RECIST 1.1
Time frame: Up to week 126
PFS based on iRECIST
Time frame: Up to week 126
Overall survival (OS)
Time frame: Up to week 126
Ran from Jun 2018 to primary completion in Dec 2019, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cemiplimab
Carcinoma, Non-Small-Cell Lung →